


越南:銀行業 2023年5月8日

買進

日標價上漲/下跌 +38% 收盤 28/04/2023 價格 18.450 越南盾 12.個月的價格目標 25.480 越南盾

股票價格與 VN-Index 之間的相關性



市值 3.5 億美元 6個月平均交易額 9.0 億美元 4.534 萬股 流通股數 自由轉讓比例 55% 外資持股 23,2% 大股東 62,2% 7,8x TS/VCSH 2023E (*) P/E 2023E (*) 3,9x P/B 2032E (*) 0.9x剩餘外資額 0,0% 2023 年的股息收益率 2,7%

源: FiinPro, (*) Yuanta Vietnam

2023年第一季度業績	Q1/2023	% QoQ	% YoY
淨利潤收入 (億越南盾)	10.227	6%	22%
淨費用收入 (億越南盾)	690	-44%	-38%
調整 TOI(億越南盾)	11.463	1%	3%
運營費用 (億越南盾)	3.568	-2%	-1%
撥備 (億越南盾)	1.850	-48%	-13%
PATMI (億越南盾)	5.024	46%	11%
NPL (%)	1,76%	+66bps +	76bps
LLR (%)	138%	-100ppt -1	.12ppt
CASA (%)	35,5% -	5,1ppt -9,2p	opt

源: 企業數據, 元大越南

分析專家:

Tran Van Tanh

+84 28 3622 6868 ext 3874

tanh.tran@yuanta.com.vn

Bloomberg code: YUTA

Quan Doi 銀行 (MBB)

第一季度的利潤增加由於撥備減少

MBB 宣布 2023 年第一季度母公司的稅後利潤 (PATMI) 達到 5 兆越南盾(+46% QoQ/+11% YoY),完成了銀行全年計劃的 25% 和我們預測的 24%。利潤增加主要是由於撥備減少。

焦點

2023 年第一季度的信貸增長 +3.8% OoO, 而行業平均增長 +2.1% OoO。

2023 年第一季度的**淨利息收入達到 10 兆 2,000 億越南盾(+6% QoQ/ +22% YoY)**。根據我們的估計,**淨息差占平均總資產的比例為 5.49%**(-7bps QoQ/ +15bps YoY)。

2023 年第一季度**,淨費用收入**達到 6,900 億越南盾(-44% QoQ / -38% YoY)。 淨保險收入下降 -40% QoQ/ -14% YoY,淨經紀費收入下降 -32% QoQ/ -65% YoY。

2023 年第一季度, **外匯業務利潤**為 3,710 億越南盾(+2% QoQ / -21% YoY)。

2023 年第一季度, **壞賬結算收入為 3,330 億越南盾(-18% QoQ / -5% YoY)**。

根據我們的估計,**2023 年第一季度的運營費用為 3 兆 6,000 億越南盾(-2% QoQ/ -1% YoY)**, CIR 比例(調整後)下降 -1.0 個百分點 QoQ/ -1.3 個百分點 YoY。

2023 年第一季度,**壞賬覆蓋率 (LLR) 下降至 138%(-100 個百分點 QoQ/-112 個百分點 YoY)**,而 MBB 的壞賬率增加至 1.76%(+66bp QoQ / +76bp YoY)。第 3 組債務增加 +128% QoQ/+161% YoY,第 5 組債務增加 +47% QoQ/+166% YoY。第 2 組債務(即需要關注的債務)增加 +114% QoQ/+243% YoY。

公司債券總價值下降 -3% QoQ 至 45 兆 5,000 億越南盾 (相當於 2023 年第一季 度末總資產的約 6.0%, 而 2022 年第四季度末為 6.4%)。

MBB 對 Novaland (NVL) 的總信貸餘額為 7 兆 9,000 億越南盾(與 2022 年第四季度相比下降 -16%),相當於 MBB 總資產的 1%。

2023 年第一季度末, **CASA 比例下降至 35.5%**(-5 個百分點 QoQ/ -9 個百分點 YoY)。

觀點

資產質量出現下降的跡象,因為壞賬急劇增加,LLR 比例在 2023 年第一季度下降,儘管我們預計第 02/2023/TT-NHNN 和第 03/2023/TT- SBV 的通告將幫助減輕撥備壓力,並降低壞賬率(上述報告)。

MBB 的 CASA 比例有所下降,但仍處於行業高位。我們預測,定期存款利率下降和信貸需求再次增加時,CASA 比例將在 2023 年第二季度和未來幾個季度復甦。

有吸引力的估值。MBB 有良好的質量,但 2023 年市盈率僅為 0.9 倍,遠低於行業中值的 1.1 倍。我們的目標價對應 12T 收益率的 41%(包括股息)。因此,我們維持買進的建議,儘管我們也認為潛在的投資風險是壞賬增加。

ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ARE LOCATED IN APPENDIX A.

Yuanta does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Appendix A: Important Disclosures

Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Ratings Definitions

BUY: We have a positive outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors add to their position.

HOLD-Outperform: In our view, the stock's fundamentals are relatively more attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

HOLD-Underperform: In our view, the stock's fundamentals are relatively less attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

SELL: We have a negative outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors reduce their position.

Under Review: We actively follow the company, although our estimates, rating and target price are under review.

Restricted: The rating and target price have been suspended temporarily to comply with applicable regulations and/or Yuanta policies.

Note: Yuanta research coverage with a Target Price is based on an investment period of 12 months. Greater China Discovery Series coverage does not have a formal 12 month Target Price and the recommendation is based on an investment period specified by the analyst in the report.

Global Disclaimer

© 2020 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold © 2020 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule15a-6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or and any form or manner, without the express written consent of Yuanta Securities (Hong Kong) Co. Limited.

Taiwan persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Attn: Research Yuanta Securities Investment Consulting 4F, 225,

Section 3 Nanking East Road, Taipei 104 Taiwan

Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Attn: Research Yuanta Securities (Hong Kong) Co. Ltd 23/F, Tower 1, Admiralty Centre 18 Harcourt Road,

Harcourt Road

Hong Kong

Korean persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Head Office Yuanta Securities Building

Euljiro 76 Jung-gu Seoul, Korea 100-845 Tel: +822 3770 3454

Indonesia persons wishing to obtain further information on any of the securities mentioned in this publication should contact:

Attn: Research
PT YUANTA SECURITIES INDONESIA
(A member of the Yuanta Group) Equity
Tower, 10th Floor Unit EFGH SCBD Lot
9
Jl. Jend. Sudirman Kav. 52-53 Tel:
(6221) – 5153608 (General)

Thailand persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Research

department

Yuanta Securities (Thailand) 127 Gaysorn Tower, 16th floor Ratchadamri Road, Pathumwan Bangkok 10330

Vietnam persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Research

department

Yuanta Securities (Vietnam) 4th Floor, Saigon Centre Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

YUANTA SECURITIES NETWORK



YUANTA SECURITIES VIETNAM OFFICE

Head office: 4th Floor, Saigon Centre, Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Wetnam

Institutional Research

Matthew Smith, CFA

Head of Research

Tel: +84 28 3622 6868 (ext. 3815) matthew.smith@yuanta.com.vn

Tam Nguyen

Analyst (Property)

Tel: +84 28 3622 6868 (ext. 3874)

tam.nguyen@yuanta.com.vn

Di Luu

Assistant Analyst

Tel: +84 28 3622 6868 (ext. 3845)

di.luu@yuanta.com.vn

Institutional Sales

Tuan-Anh Nguyen

Sales Trader

Tel: +84 28 3622 6868 (ext. 3909) anh.nguyen2@yuanta.com.vn

Vi Truong

Sales Trader

Tel: +84 28 3622 6868 (ext. 3940)

vi.truong@yuanta.com.vn

Binh Truong

Deputy Head of Research (O&G, Energy) Tel: +84 28 3622 6868 (3845)

binh.truong@yuanta.com.vn

Tanh Tran

Analyst (Banks)

Tel: +84 28 3622 6868 (3874)

tanh.tran@yuanta.com.vn

An Nguyen

Assistant Analyst

Tel: +84 28 3622 6868 (ext. 3845) an.nguyen@yuanta.com.vn

Hillen Lee

\$\$kbsTFadder T6E1:+8942883662268688

hhiran 1200 yuantta connum

Datat Britini

\$28366226868((ext. 3994))

databbio@yvanteccomynn